Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10976 - 11000 of 11900 in total
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
Matched Description: … PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections …
Investigational
Ilomastat is a broad-spectrum matrix metalloproteinase inhibitor.
Experimental
Matched Description: … Ilomastat is a broad-spectrum matrix metalloproteinase inhibitor. …
Glibornuride is a sulfonylurea-type anti-diabetic drug.
Investigational
Withdrawn
Matched Description: … Glibornuride is a sulfonylurea-type anti-diabetic drug. …
Bamifylline is a selective A1 adenosine receptor antagonist.
Experimental
Matched Description: … Bamifylline is a selective A1 adenosine receptor antagonist. …
Protego-PD is a post-delivery placental extract.
Investigational
Matched Description: … Protego-PD is a post-delivery placental extract. …
Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).
Investigational
Matched Description: … Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial …
SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects).
Investigational
Matched Description: … SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability …
Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).
Investigational
Matched Description: … Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ …
Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).
Investigational
Matched Description: … investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A
Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
Investigational
Matched Description: … Domagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety …
CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).
Investigational
Matched Description: … CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and …
Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)).
Investigational
Matched Description: … Rovatirelin is under investigation in clinical trial NCT01384435 (A Phase II Double Blind Comparative …
GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough).
Investigational
Matched Description: … GSK2798745 is under investigation in clinical trial NCT03372603 (A Study to Assess the Effectiveness …
LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy for patients with Parkinson's disease and Gaucher disease.
Investigational
Matched Description: … LY3884961 (previously PR001) is being developed by Prevail Therapeutics as a single-dose gene therapy …
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
Matched Description: … MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) …
MOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus warts in the oral cavity of HIV-positive patients.
Investigational
Matched Description: … MOR-22, a Natural human lymphoblastoid interferon-alpha, is currently being investigated to treat papillomavirus …
The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational
Matched Description: … ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a
Pirepemat is under investigation in clinical trial NCT05258071 (A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)).
Investigational
Matched Description: … Pirepemat is under investigation in clinical trial NCT05258071 (A Clinical Study Evaluating Efficacy …
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing...
Investigational
Matched Description: … ., a privately held biopharmaceutical company. ... HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. …
7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan DB00762, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative...
Investigational
Matched Description: … 7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan ... [DB00762], a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. …
OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of...
Investigational
Matched Description: … It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple …
Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors. It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high levels of intrinsic oxidative stress. In contrast, Bardoxolone in...
Investigational
Matched Description: … It is a synthetic triterpenoid and a highly potent activator of redox-sensitive signaling pathways that …
Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine...
Experimental
Investigational
Matched Description: … Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. ... The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug …
BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.[L15002, L15007] BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728)...
Investigational
Matched Description: … BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a ... [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles …
Displaying drugs 10976 - 11000 of 11900 in total